Becton Dickinson (BDX) · Medical Devices
Becton Dickinson Q3 FY2026 earnings: summary, key numbers & outlook
Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
BD's first full quarter as a focused MedTech company showed broad growth across all four segments, led by BioPharma Systems' GLP-1 injection pen collaboration in Brazil and Interventional's new laser launch.
BD completed its separation of the Biosciences and Diagnostic Solutions business into Waters in February, and this was its first full quarter as 'New BD' with four segments. All four grew. Advanced Patient Monitoring was the fastest-growing unit, and U.S. sales outpaced international. Product news included a Vizient Innovative Technology contract for the CentroVena One insertion system, the Elyra Thulium Fiber Laser System for kidney stone care, and an EMS semaglutide launch in Brazil on BD's Vystra Injection Pen.
Management is steering toward a simpler, more focused company built around key growth platforms, under its 'Excellence Unleashed' strategy. It has exited operational activities and projects that no longer fit, taking $450 million of non-cash impairment charges over nine months. The main risks are the Alaris infusion system's timing for return to market in the U.S., tariffs, Middle East supply disruption, and changes in U.S. vaccine and pharmaceutical policy that could reduce demand.
Key numbers
- Revenue · GAAP
- $5.0B
- Diluted EPS from continuing operations · GAAP
- $1.64
- Adjusted diluted EPS from continuing operations · non-GAAP
- $3.23
- Net income from continuing operations · GAAP
- $451.0M
- Operating income · GAAP
- 663.0M
- Nine-month cash from continuing operations · GAAP
- $2.1 billion
- Nine-month free cash flow · non-GAAP
- $1.7 billion
up 5.4% reported, 4.4% FXN
up 4.5% from a year ago
up 4.9% from a year ago
flat (up 0.1%) from a year ago
down 10.3% from a year ago
up 33.3% year to date
up 44.6% year to date
| Segment or metric | Value | Change |
|---|---|---|
| Medical Essentials | $1.7B | up 4.5% reported, 3.2% FXN |
| Connected Care | $1.2B | up 4.9% reported, 4.4% FXN |
| BioPharma Systems | $670.0M | up 6.6% reported, 5.2% FXN |
| Interventional | $1.4B | up 6.4% reported, 5.5% FXN |
| Advanced Patient Monitoring | $309.0M | up 10.9% reported, 11.2% FXN |
| Specimen Management | $511.0M | up 8.7% reported, 7.0% FXN |
| Peripheral Intervention | $552.0M | up 7.8% reported, 6.1% FXN |
Where each number comes from
- Revenue: “Revenues | $4,983 | $4,726 | 5.4% | 4.4% Reported Diluted Earnings per Share | $1.64 | $1.57 | 4.5% | 3.8%”
- Diluted EPS from continuing operations: “Reported Diluted Earnings per Share | $1.64 | $1.57 | 4.5% | 3.8% Adjusted Diluted Earnings per Share1 | $3.23 | $3.08 | 4.9% | 3.9%”
- Adjusted diluted EPS from continuing operations: “Adjusted Diluted Earnings per Share1 | $3.23 | $3.08 | 4.9% | 3.9% 1Represents a non-GAAP financial measure; refer to reconciliations”
- Net income from continuing operations: “Income tax provision | 102 | 118 | (13.2) Net Income from Continuing Operations | 451 | 451 | 0.1 (Loss) Income from Discontinued Operations, Net of Tax”
- Operating income: “Total Operating Costs and Expenses | 4,320 | 3,986 | 8.4 Operating Income | 663 | 739 | (10.3) Interest expense | (132) | (152) | (13.4)”
- Nine-month cash from continuing operations: “Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion”
- Nine-month free cash flow: “Year-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billion”
- Medical Essentials: “Medical Essentials2 | $1,675 | $1,602 | 4.5% | 3.2% Connected Care2 | $1,224 | $1,166 | 4.9% | 4.4%”
- Connected Care: “Connected Care2 | $1,224 | $1,166 | 4.9% | 4.4% BioPharma Systems2 | $670 | $629 | 6.6% | 5.2%”
- BioPharma Systems: “BioPharma Systems2 | $670 | $629 | 6.6% | 5.2% Interventional2 | $1,414 | $1,328 | 6.4% | 5.5%”
- Interventional: “Interventional2 | $1,414 | $1,328 | 6.4% | 5.5% Total Revenues | $4,983 | $4,726 | 5.4% | 4.4%”
- Advanced Patient Monitoring: “Advanced Patient Monitoring | 189 | 176 | 7.4 | 120 | 102 | (1) | 17.1 | 17.8 | 309 | 278 | (1) | 10.9 | 11.2”
- Specimen Management: “Specimen Management | 274 | 240 | 14.0 | 237 | 230 | 8 | 3.1 | (0.2) | 511 | 470 | 8 | 8.7 | 7.0”
- Peripheral Intervention: “Peripheral Intervention | $294 | $271 | 8.4 | $258 | $241 | $9 | 7.2 | 3.5 | $552 | $512 | $9 | 7.8 | 6.1”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q3 FY2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $5.0B | +5.4% | +5.7% |
| Operating income | $663.0M | −10.3% | +612.9% |
| Net income | $377.0M | −34.3% | — |
| Diluted EPS | $1.37 | −31.5% | — |
| Operating margin | 13.3% | −2.3 pts | +11.3 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Adjusted diluted EPS | fiscal 2026 | $12.62 to $12.72 |
Key takeaways
First full quarter as focused 'New BD'
Following the February spin-off and combination with Waters, BD operates four segments and said the quarter showed early benefits of a more focused MedTech company. All four segments grew.
BioPharma Systems tied to GLP-1 self-injection
BD announced a collaboration with EMS, a leading Brazilian pharmaceutical company, to launch semaglutide using BD's Vystra Injection Pen platform. It extends BD's role in access to obesity and type 2 diabetes therapies.
Interventional expanded kidney stone portfolio
BD launched the Elyra Thulium Fiber Laser System, designed to improve efficiency, versatility and workflow for urology teams. Interventional also grew 6.4% as reported.
Vizient award validates CentroVena One
The BD CentroVena One Insertion System won a Vizient Innovative Technology contract. BD describes it as designed to simplify central line insertion and improve patient and clinician safety.
Portfolio pruning under Excellence Unleashed
BD recorded $450 million of non-cash impairments to exit activities and projects no longer aligned with its strategy. The goal is simpler operations and resources behind its most value-creating platforms.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $5.4B * |
| Q1 FY25 | $5.2B |
| Q2 FY25 | $4.5B |
| Q3 FY25 | $4.7B |
| Q4 FY25 | $8.3B * |
| Q1 FY26 | $5.3B |
| Q2 FY26 | $4.7B |
| Q3 FY26 | $5.0B |
Data
| Q1 FY25 | $1.04 |
| Q2 FY25 | $1.07 |
| Q3 FY25 | $2.00 |
| Q1 FY26 | $1.34 |
| Q2 FY26 | -$1.11 |
| Q3 FY26 | $1.37 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 11.4% |
| Q1 FY25 | 8.8% |
| Q2 FY25 | 8.5% |
| Q3 FY25 | 15.6% |
| Q4 FY25 | 14.1% |
| Q1 FY26 | 10.5% |
| Q2 FY26 | 2.0% |
| Q3 FY26 | 13.3% |
Data
| Q1 FY25 | $588.0M |
| Q1 FY26 | $549.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
What did BD launch or announce in Q3 FY2026?
BD launched the Elyra Thulium Fiber Laser System for kidney stone care, won a Vizient Innovative Technology contract for CentroVena One, and announced an EMS collaboration for a semaglutide launch in Brazil using the Vystra Injection Pen platform.
What is BD's strategy after the Waters transaction?
BD, now called New BD, is a more focused MedTech company with four segments, concentrating on key growth platforms, innovation and BD Excellence under its Excellence Unleashed strategy.
Which BD businesses grew fastest this quarter?
Advanced Patient Monitoring grew 10.9% reported and Specimen Management 8.7%. Among segments, BioPharma Systems rose 6.6% and Interventional 6.4%.
How is BD participating in the GLP-1 market?
Through a collaboration with EMS in Brazil, whose semaglutide launch will use BD's Vystra Injection Pen platform for self-injection by patients with obesity and type 2 diabetes.
What are the main risks BD flags for its plan?
BD cites tariffs, Middle East supply chain disruption, U.S. policy changes affecting vaccines and pharmaceuticals, and the timing of the Alaris infusion system's return to market in the U.S.
Documents
SEC filing